Ind-Swift Laboratories Ltd
30 Oct 2026 12:00 AM
Ind-Swift Laboratories Ltd consolidated sales up 25.60% on year in Q3FY2026, net profit surged by 38.99%,
Ind-Swift Laboratories Ltd share price headed higher 7.75% to Rs 408.85 after the company`s net profit jumped 38.99% to Rs 34.15 crore, while revenue from operations increased sharply by 25.60% to Rs 240.46 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, rising 4.44%. It has improved by 5.74% over last one week and moved up slightly by 0.60% in last one month while the market capitalization of Ind-Swift Laboratories Ltd has significantly gained 24.73% and 81.87% in the same period respectively.
Profit before tax (PBT) of Ind-Swift Laboratories Ltd stood at Rs 43.38 crore in Q3 FY26, surging by 319.54% year-on-year, and expanding by 33.23% quarter-on-quarter. EBITDA came in at Rs 38 crore, tumbling by 962.41% YoY and rallying 46.86% sequentially.
Total expenses witnessed a sharp rise of 22.45% to Rs 202.77 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 92.87 crore, going up by 13.59% YoY, while employee benefits expense was at Rs 37.97 crore, slipping by 4.02% YoY.
For the TTM ended FY26, revenue from operations advanced 15.56% to Rs 649.14 crore, while net profit witnessed a sharp fall of 82.82% to Rs 43.03 crore, compared to previous TTM. EBITDA tumbled by 9564% to Rs 0.16 crore, and PBT tanked by 80.31% to Rs 50.76 crore compared to previous TTM.
The company`s consolidated net cash flow from operating activities stood at Rs 68.17 crore in FY26, as against Rs 28.69 crore in FY25.
Ind-Swift Laboratories Ltd soared by 297.52% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 12.76% during the same period.
Ind-Swift Laboratories Ltd
29 Oct 2026 12:00 AM
Ind-Swift Laboratories Ltd consolidated sales up 25.60% on year in Q3FY2026, net profit saw a strong growth of 38.99%,
Ind-Swift Laboratories Ltd share price inched up 3.04% to Rs 379.45 after the company`s net profit soared by 38.99% to Rs 34.15 crore, while revenue from operations increased sharply by 25.60% to Rs 240.46 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, rising 4.24%. It has marginally improved by 3.87% over last one week and crept higher by 0.06% in last one month while the market capitalization of Ind-Swift Laboratories Ltd has improved by 9.60% and 68.79% in the same period respectively.
Profit before tax (PBT) of Ind-Swift Laboratories Ltd stood at Rs 43.38 crore in Q3 FY26, expanding by 319.54% year-on-year, and surging by 33.23% quarter-on-quarter. EBITDA came in at Rs 38 crore, crashing by 962.41% YoY and jumping 46.86% sequentially.
Total expenses surged 22.45% to Rs 202.77 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 92.87 crore, increasing 13.59% YoY, while employee benefits expense was at Rs 37.97 crore, softening 4.02% YoY.
For the TTM ended FY26, revenue from operations advanced 15.56% to Rs 649.14 crore, while net profit tanked by 82.82% to Rs 43.03 crore, compared to previous TTM. EBITDA tumbled by 9564% to Rs 0.16 crore, and PBT plunged by 80.31% to Rs 50.76 crore compared to previous TTM.
The company`s consolidated net cash flow from operating activities stood at Rs 69.88 crore in FY26, as against Rs 28.69 crore in FY25.
Ind-Swift Laboratories Ltd surged by 267.15% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 13.45% during the same period.
Ind-Swift Laboratories Ltd
15 Oct 2026 12:00 AM
Ind-Swift Laboratories to review quarterly and half-year financial results on October 29,
Ind-Swift Laboratories Ltd. will hold a board meeting on Thursday, October 29, 2026, to consider and approve the standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2026, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Ind-Swift Laboratories Ltd
08 Oct 2026 12:00 AM
Ind-Swift Laboratories allotted shares to Essix Biosciences for Rs 20.58 crore via warrant conversion,
Ind-Swift Laboratories Limited announced that its Preferential Issue Committee has approved the allotment of 14,00,000 equity shares with a face value of Rs 10 each to Essix Biosciences Limited, a promoter group entity, upon the conversion of an equal number of fully convertible warrants. The conversion involved a consideration of Rs 147 per warrant, totaling Rs 20,58,00,000, and was executed at an issue price of Rs 196 per warrant. Consequently, the company`s paid-up equity share capital increased from Rs 86,71,15,580 comprising 8,67,11,558 equity shares to Rs 86,96,15,580 comprising 8,69,61,558 equity shares.
Ind-Swift Laboratories Ltd
05 Oct 2026 12:00 AM
Ind-Swift Laboratories confirms regulatory compliance for the September quarter, per Alankit Assignments,
Ind-Swift Laboratories Limited submitted a certificate to the Bombay Stock Exchange and National Stock Exchange of India confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as received from Alankit Assignments Limited, the company`s Registrar and Share Transfer Agent.
Subscribe for our
newsletter
newsletter
HSL Mobile App